Research peptide · GH axis research
CJC-1295 (DAC)
Also known as CJC-1295 with drug affinity complex · DAC:GRF
A 29-residue analog of growth hormone releasing factor (1-29) carrying an added lysine bearing a maleimidopropionamide group, designed to form a covalent conjugate with serum albumin. Molecular formula C165H269N47O46, average molecular weight 3647.19 g/mol.
- Compound type
- Research peptide
- Research area
- GH axis
- Formula
- C165H269N47O46
- Average mass
- 3,647.189 Da
- Monoisotopic mass
- 3,645.0155 Da
- Length
- 29 residues
- PubChem
- CID 91971820
What it is
CJC-1295 with DAC is a chemically modified analog of growth hormone releasing factor, hGRF(1-29). Its molecular formula is C165H269N47O46, its average molecular weight is 3647.19 g/mol and its monoisotopic mass is 3645.02. It is indexed in PubChem under CID 91971820.
The backbone is a tetrasubstituted form of hGRF(1-29). What distinguishes this molecule is the drug affinity complex: an added lysine at the C terminus whose side chain carries an N-epsilon-3-maleimidopropionamide group, a thiol-reactive handle around which the molecule was designed 1.
Discovery and origin
The compound was described in 2005 by Jette and colleagues at ConjuChem in Montreal. Three maleimido derivatives of hGRF(1-29) were synthesized and bioconjugated to serum albumin ex vivo, and the derivative designated CJC-1295 was selected from that set for further characterization 1.
Structure and chemistry
The chemistry that defines the molecule is the Michael addition of a free thiol to the maleimide ring, which forms a stable thioether. In the published work the target thiol was Cys34 of serum albumin, the single free cysteine on that protein, and conjugation produced a species of albumin-like mass 1. The compound is therefore reactive toward any accessible thiol, including reducing agents.
The 29-residue peptide carries several basic residues and ionizes readily in positive mode, so the useful ions are the multiply charged series: the triply, quadruply and quintuply protonated ions fall near m/z 1216.01, 912.26 and 730.01.
How it is studied in the laboratory
The founding study combined cell culture and rodent work. The in vitro system was cultured rat anterior pituitary cells with growth hormone release into the medium as the readout, and the albumin conjugates were also tested for stability against dipeptidyl peptidase IV 1. The rodent component used normal male Sprague Dawley rats, with plasma growth hormone measured over a two-hour window and the area under the curve compared against unmodified hGRF(1-29); the paper reported a roughly four-fold larger area under the curve for CJC-1295, and a Western blot of rat plasma showed an immunoreactive species on the band corresponding to serum albumin 1.
The compound also appears in analytical method development for growth hormone releasing hormone analogs, using liquid chromatography coupled to tandem mass spectrometry on fortified matrices 2.
Analytical notes
Identity is confirmed by liquid chromatography coupled to mass spectrometry in positive ion mode, reading the multiply charged envelope and deconvoluting it to the intact mass. Calculations on the monoisotopic mass of 3645.02 rather than the average mass of 3647.19 shift the expected ions, so a certificate should state its convention.
The maleimide group is the analytical weak point. It hydrolyzes to the ring-opened maleamic acid in aqueous buffer, particularly above neutral pH, adding 18 to the mass and destroying the thiol reactivity that defines the compound, so a mass measurement alone does not establish that the reactive handle is intact. On reversed-phase HPLC the informative peaks are deletion sequences, the hydrolyzed maleimide species and any thiol adducts formed during handling.
Storage and handling in the laboratory
As supplied, the material is a lyophilized powder, stored at -20 degrees Celsius, sealed and protected from light and moisture. Thiol-free buffers are essential for any work where the maleimide must survive, and neutral to slightly acidic conditions slow its hydrolysis.
Open questions in the literature
No experimental structure of the conjugate has been published, so the orientation of the peptide once tethered to albumin is inferred rather than observed. Site heterogeneity in conjugate formation, and the behavior of the molecule in albumin-free systems, are not documented.
Identity check
A mass-spectrometry result for CJC-1295 (with DAC) should show peaks near these values. A result more than about one unit away is worth a question to the testing lab. Salt forms such as acetate or TFA do not move these peaks, though they do mean less peptide in each milligram of powder.
| Ion | Expected m/z |
|---|---|
| [M+3H]3+ | 1216.01 |
| [M+4H]4+ | 912.26 |
| [M+5H]5+ | 730.01 |
References
- Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. Source
- Memdouh S, Gavrilovic I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021;13(11-12):1871-1887. doi:10.1002/dta.3183. Source
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.
